Search Results:
CLINICAL TRIAL 19627
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Disease Site: Lymphoma, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 19829
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20069
A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)
Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20578
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Disease Site: Lymphoma, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20608
A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Disease Site: Chronic Leukemia (CLL, CML), Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Disease Site: Hodgkin's Lymphoma, Lymphoid Leukemia, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20751
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20831
A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21094
An Open Label, Multi-Cohort, Multi-Center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination with Chemotherapy in Patients with Advanced T-cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21096
A Phase I Study of Duvelisib in Combination with CC-486 in Lymphoid Malignancy
Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21122
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21366
Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21392
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
Disease Site: Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Hematopoietic
View Trial DetailsCLINICAL TRIAL 21412
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 plus Standard of Care versus Placebo plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21580
A Phase 1 Study of PBCAR19B in Subjects with CD19-expressing Malignancies
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21623
A Phase 1/2 Study of bbT369, a Dual Targeting CAR T cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B cell Non-Hodgkin s Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21634
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21696
A Phase 1/2 Dose-Escalation and Dose-Expansion of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia /Lymphoblastic Lymphoma (T-ALL)/Lymphoblastic Lymphoma (LBL)
Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21775
Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine as a Single Agent in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21892
A Phase 2, Single-Arm, Open-Label Study using Itacitinib as Pre-Modulation in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CAR-T-Cell Therapy
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 22539
Request for Single Patient Emergency Access Use of Axicabtagene Ciloleucel
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21752
Chimeric Antigen Receptor T-Cell Therapy: Neurocognitive Effects and Patient-Reported Outcomes
Disease Site: Hodgkin's Lymphoma, Leukemia, other, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Hematopoietic
View Trial Details
